Alzheimer's disease: clinical trials and drug development

By F. Mangialasche, Alina Solomon, Bengt Winblad, P. Mecocci, Miia Kivipelto. Lancet Neurology, 2010

1,176 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders (2011, positive): “However, most preclinical and clinical studies have shown that such drugs are unable to cure or control human neurological disorder”
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics (2011, neutral): “With reference to an agent that targets plaques — such as bapineuzumab and other therapeutic agents that are currently in developmen”
APP mouse models for Alzheimer's disease preclinical studies (2017, neutral): “Given the grim epidemiological forecast, scientifically based strategies to prevent AD are urgently needed, as evidenced by the fact that in the previous two decades more than 400 medication candidates failed to reach the clinic (Mangialasche et al , 2010).”